Company Policy and Action Guidelines

The purpose of the Shionogi Group's corporate activities is, as expressed in the opening of its Company Policy, to "supply the best possible medicine to protect the health and wellbeing of the patients we serve." This eternal and unwavering corporate philosophy is a statement of our vision and value to society. To achieve and live by the Company Policy, we have formulated Action Guidelines, which all Shionogi employees share and embrace as norms for daily activities. Through activities based on the Company Policy and the Action Guidelines, Shionogi will continue to contribute to patients, physicians and other healthcare providers, shareholders and investors, and furthermore to society as a whole.

Shionogi's purpose:

Shionogi strives constantly to supply the best possible medicine to protect the health and wellbeing of the patients we serve.

For this purpose‚ Shionogi will need to:

Pursue the search for even better medicines.
Produce even better medicines.
Promote awareness of these better medicines to more people so that more people will be able to use these medicines.
Research, produce and promote in an even more economical manner.

For this purpose‚ Shionogi people will need to:

Strive ceaselessly day after day to improve their skills.
Strive ceaselessly day after day to improve as human beings.

As a result‚ Shionogi people will:

Find even greater satisfaction in their daily work and in their daily lives.
Find even greater improvement in the quality of their lives.
Find even greater prosperity in their lives.

 

(Established on January, 1957)

Shionogi’s Action Guidelines

Mission

We will deliver pharmaceuticals that offer an even higher level of satisfaction to patients, their families, and healthcare providers and improve the quality of life for patients and their families.

Vision

A company with a strong presence worldwide

A company that has pride and dreams and embraces challenges

Value

Customer focus Trust Professionalism On-site orientation

Respect for the individual

(Formulated in 2004)